Agilent Technologies and SomaLogic Enter Agreement to Expand Access to Cutting-Edge Proteomic Techno

Before you go, we thought you'd like these...
Before you go close icon

Agilent Technologies and SomaLogic Enter Agreement to Expand Access to Cutting-Edge Proteomic Technology

Microarray-based SOMAscan Assay to Be Installed at Select Academic and Contract Research Centers

SANTA CLARA, Calif. & BOULDER, Colo.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYS: A) and SomaLogic Inc. (a privately held biotechnology company) announced today that they have entered into an agreement to expand access to SomaLogic's unbiased protein biomarker discovery platform.

The companies will initially place SomaLogic's SOMAscan proteomic assay, which employs custom Agilent microarrays in its workflow, in select academic and contract research centers. Although the SOMAscan assay is already available to researchers directly from SomaLogic as a service, this planned roll-out is aimed at meeting the rapidly growing demand for access to SomaLogic's highly multiplexed, cost-effective proteomic analyses.

"This agreement will greatly enhance our current microarray offerings by expanding them into the rapidly growing proteomics market," said Jacob Thaysen, vice president and general manager of Agilent's Genomics Solutions Division. "SomaLogic's cutting-edge proteomic technology makes them an ideal partner for us to increase our presence in this growing market."

"Agilent's custom microarrays have been a critical element in our development of the SOMAscan assay over the past several years," said Larry Gold, Ph.D., chairman and CEO of SomaLogic. "We are delighted that our partnership is expanding to make the technology even more accessible to researchers everywhere."

Terms of the agreement were not disclosed.

About SomaLogic

SomaLogic, Inc., is a privately held biomarker discovery and clinical diagnostics company based in Boulder, Colo. The company's mission is to use its proprietary proteomic technology to develop a wide range of enhanced protein-analysis tools and reagents for the life sciences community, to facilitate biomarker discovery and validation for diagnostic and therapeutic applications, and to develop and commercialize clinical diagnostic products that will improve the delivery of health care by offering timely and accurate diagnostic information to physicians and their patients. Further information about SomaLogic can be found at

About SOMAscan/SOMAmers

The SOMAscan proteomic assay utilizes SomaLogic's proprietary Slow Off-rate Modified Aptamer (SOMAmer) affinity reagents to cost-effectively detect and measure 1129 protein analytes across a wide dynamic range in as little as 50 µl of biological sample, with a throughput of nearly a thousand samples per week, producing millions of useful data points in a short time. Further information about the applications of this breakthrough proteomic technology can be found at

About Agilent Technologies

Agilent Technologies Inc. (NYS: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics, and communications. The company's 20,500 employees serve customers in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal 2012. Information about Agilent is available at

NOTE TO EDITORS: Further technology, corporate citizenship, and executive news is available on the Agilent news site at


Agilent Technologies Inc.
Eric Endicott, +1 408-553-2005
SomaLogic, Inc.
Fintan R. Steele, Ph.D., +1 720-214-3080

KEYWORDS:   United States  North America  California  Colorado


The article Agilent Technologies and SomaLogic Enter Agreement to Expand Access to Cutting-Edge Proteomic Technology originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

People are Reading